Johnson & Johnson Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Johnson & Johnson wird voraussichtlich ein Umsatzwachstum verzeichnen at 4.4% per annum.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	4.4%
Zukünftige Eigenkapitalrendite	38.6%
Analystenabdeckung	Low
Zuletzt aktualisiert	20 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors

May 16

Johnson & Johnson's (NYSE:JNJ) Dividend Will Be Increased To $1.24

May 03

Johnson & Johnson (NYSE:JNJ) Will Pay A Larger Dividend Than Last Year At $1.24

Apr 19

Johnson & Johnson: Buy This Bargain Before It's Gone

Apr 18

Johnson & Johnson Q1 Earnings Preview: Shockwave Could Be A Good Fit Despite Headwinds

Apr 11

Gewinn- und Umsatzwachstumsprognosen

NYSE:JNJ - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	95,876	N/A	24,380	30,376	5
12/31/2025	92,105	N/A	23,113	29,321	4
12/31/2024	88,785	N/A	22,167	28,103	4
3/31/2024	85,648	17,072	18,234	23,191	N/A
12/31/2023	85,159	13,326	17,778	22,791	N/A
10/1/2023	98,656	13,992	15,737	20,278	N/A
7/2/2023	97,301	13,993	14,547	19,073	N/A
4/2/2023	77,458	10,730	16,207	20,472	N/A
1/1/2023	79,990	16,370	17,185	21,194	N/A
10/2/2022	84,855	17,879	17,739	21,576	N/A
7/3/2022	88,197	17,236	19,950	23,582	N/A
4/3/2022	94,880	19,830	19,733	23,315	N/A
1/2/2022	78,740	17,801	19,758	23,410	N/A
10/3/2021	91,446	17,880	22,461	26,021	N/A
7/4/2021	89,190	17,767	22,564	26,114	N/A
4/4/2021	84,214	15,115	20,853	24,252	N/A
1/3/2021	82,584	14,714	20,189	23,536	N/A
9/27/2020	80,856	16,986	18,307	21,591	N/A
6/28/2020	80,503	15,185	17,443	20,735	N/A
3/29/2020	82,729	17,166	19,764	23,231	N/A
12/29/2019	82,059	15,119	19,918	23,416	N/A
9/29/2019	81,706	14,151	19,706	23,262	N/A
6/30/2019	81,325	16,332	18,377	22,007	N/A
3/31/2019	81,593	14,679	18,470	22,138	N/A
12/30/2018	81,581	15,297	18,531	22,201	N/A
9/30/2018	81,382	1,542	18,470	22,062	N/A
7/1/2018	80,684	1,372	18,493	22,056	N/A
4/1/2018	78,693	1,245	18,372	21,749	N/A
12/31/2017	76,450	1,300	N/A	21,056	N/A
10/1/2017	74,361	15,827	N/A	21,604	N/A
7/2/2017	72,531	16,335	N/A	20,699	N/A
4/2/2017	72,174	16,505	N/A	19,491	N/A
1/1/2017	71,890	16,540	N/A	18,767	N/A
10/2/2016	71,595	15,941	N/A	17,199	N/A
7/3/2016	70,877	15,027	N/A	17,978	N/A
4/3/2016	70,182	15,546	N/A	18,886	N/A
1/3/2016	70,074	15,409	N/A	19,569	N/A
9/27/2015	70,517	14,715	N/A	18,849	N/A
6/28/2015	71,882	16,106	N/A	17,363	N/A
3/29/2015	73,590	15,916	N/A	17,420	N/A
12/28/2014	74,331	16,323	N/A	18,710	N/A
9/28/2014	74,232	17,321	N/A	18,245	N/A
6/29/2014	73,340	15,554	N/A	19,538	N/A
3/30/2014	71,722	15,061	N/A	19,060	N/A
12/29/2013	71,312	13,831	N/A	17,414	N/A
9/29/2013	70,515	12,879	N/A	16,651	N/A
6/30/2013	69,992	12,865	N/A	15,684	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von JNJ über der Sparquote liegt (2.4%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von JNJ schneller wachsen werden als der Markt US

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von JNJ in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: JNJDie Einnahmen des Unternehmens (4.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: JNJDie Einnahmen des Unternehmens (4.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: JNJDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (38.6%)

Johnson & Johnson Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Johnson & Johnson Revises Earnings Guidance for the Full Year of 2024

Recent updates

Johnson & Johnson Announces Positive Topline Results from the Pivotal Phase 3 GRAVITI Investigational Study of TREMFYA® Subcutaneous (SC) Induction Therapy in Adult Patients with Moderate to Severe Active Crohn's Disease

Beasley Allen and Levin Papantonio Announces Class Action Lawsuit Against Johnson & Johnson

Johnson & Johnson Announces TALVEY® (Talquetamab-Tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma

There's Reason For Concern Over Johnson & Johnson's (NYSE:JNJ) Price

New major risk - Revenue and earnings growth

Johnson & Johnson to Report Q3, 2024 Results on Oct 15, 2024

Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Johnson & Johnson Announces Pivotal Study of Seltorexant Shows Statistically Significant and Clinically Meaningful Improvement in Depressive Symptoms and Sleep Disturbance Outcomes

Johnson & Johnson: Market Will Regret The Overreaction

Johnson & Johnson: Vital Signs Decent, A Compelling Value Case

Johnson & Johnson Announces the First Phase 3 Results for Tremfa® (Guselkumab) in Adult Patients with Moderate to Severe Active Crohn's Disease Program

We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Proteologix, Inc. for $850 million.

Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors

Upcoming dividend of US$1.24 per share

Johnson & Johnson Announces Updated Results from an Open-Label, Multicenter, Multi-Cohort Phase 1 Study of the Safety and Efficacy of TAR-210

Johnson & Johnson's (NYSE:JNJ) Dividend Will Be Increased To $1.24

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Johnson & Johnson (NYSE:JNJ) Will Pay A Larger Dividend Than Last Year At $1.24

First quarter dividend increased to US$1.24

Johnson & Johnson: Buy This Bargain Before It's Gone

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Johnson & Johnson Revises Earnings Guidance for the Full Year of 2024

Johnson & Johnson Announces Planned Presentation of New Non-Clinical Studies

Johnson & Johnson Q1 Earnings Preview: Shockwave Could Be A Good Fit Despite Headwinds

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken